Uses of monoclonal antibody 8H9

Details Uses of monoclonal antibody 8H9 Uses of monoclonal antibody 8H9

2003-03-06

2010-06-22

Aeder, Sean E (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

Reexamination Certificate

active

07740845

ABSTRACT:
This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.

REFERENCES:
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5693762 (1997-12-01), Queen et al.
patent: 6132718 (2000-10-01), Hansen
patent: 6326471 (2001-12-01), Kokolus et al.
patent: 6632431 (2003-10-01), Wu
patent: 2002/0102264 (2002-08-01), Cheung
patent: 2002/0132983 (2002-09-01), Junghans
patent: 2003/0103963 (2003-06-01), Cheung
patent: 2003/0149998 (2003-08-01), Blatcher et al.
patent: WO 03/075846 (2003-09-01), None
patent: WO 2004/050849 (2004-06-01), None
Modak et al (Proceedings of ASCO, 1998, 17: 445a).
Li et al (Cancer Immunol Immunother, 2000, 49:243-252).
Supplemental European Search Report for EP 01 98 3999, filed May 16, 2003, for Sloan-Kettering Institute for Cancer Research et al., dated Jul. 26, 2005.
Modak. et al., “Dislaloganglioside GD2 and antigen 8H9; Potential targets for antibody-based immunotherapy against desmoplastic small round cell tumor (DSRCT) and rhabdomyosarcoma (RMS)”, Proceedings of the American Association for Cancer Search Annual Meeting, vol. 40, Mar. 1999, p. 474.
International Search Report for PCT/US03/07004, filed Mar. 6, 2003 for Sloan Kettering Institute for Cancer Research et al., dated Jun. 7, 2005.
Anja Krause, Hong Fen Guo, Jean-Baptiste Latouche, Cuiwen Tan, Nai-Kong V. Cheung, Michael Sadelain, Antigen-Dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes, J. Exp. Med. vol. 186, No, 4, pp. 619-626 (1998).
Cheung Nai-Kong V. et al., “Anti-idiotypic Antibody Facilitates scFv Chimeric Immune Receptor Gene Transduction and Clonal Expansion of Human Lymphocytes for Tumor Therapy”, Hybridoma and Hybridomics vol. 22, No. 4, pp. 209-218 (2003).
Cheung Nai-Kong V. et al., “Anti-idiotypic Antibody as the Surrogate Antigen for Cloning scFv and its Fusion Proteins”, Hybridoma and Hybridomics vol. 21, No. 6, pp. 433-443 (2002).
Cheung Nai-Kong V., “Monoclonal Antibody-based Therapy for Neuroblastoma”. Current Oncology Reports, vol. 2, No. 5, pp. 547-553 (2000).
International Patent Publication No. WO 02/32375 for Sloan-Kettering Institute for Cancer Research, Filed Oct. 18, 2001 for “Uses of Monoclonal Antibody 8H9”.
Modak S., Guo H.F., Humm J.L., Smith-Jones P.M., Larson S.M., Cheung N.K., “Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9”, Cancer Biother Radiopharm. 20(5):534-46 (2005).
Modak S., Guo H.F., Humm J., Larson S.M., Cheung N.K., “Novel Tumor Target for Antibody-based Therapy of Rhabdomyosarcoma and Other Pediatric Solid Tumors”, Journal of Pediatric Hematology/Oncology 22(4) (2000).
Modak S., Guttekin S.H., Kramer K., Guo H.F., Rosenfeld M.R., Ladanyi M., Larson S.M., Cheung Nai Kong V., “Novel Tumor-associated Surface Antigen: Broad Distribution among Neuroectodermal Mesenchymal and Epithelial Tumors with Restructured Distribution in Normal Tissues”, Proceedings of ASCO vol. 17 (1998).
Modak S., Kramer K., Guitekin S.H., Guo H.F., Larson S M., Cheung N.K., “Monoclonal Antibody 8H9: Specific for a Novel Tumor Antigen on Human Neuroblastoma”, Medical and Pediatric Oncology, vol, 35, No. 6 (2000).
Queen, et al. “A humanized antibody that binds to the interleukin receptor”, Proc. Natl. Acad. Sci USA, vol. 86, pp. 10029-10033, Dec. 1989.
PCT International Preliminary Examination Report for Sloan-Kettering Institute for Cancer Research Int'l Application No. PCT/US01/32565, Filed Oct. 18, 2001, Dated Apr. 27, 2006.
PCT Written Opinion of the International Preliminary Examining Authority for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/US01/32565, Filed Oct. 18, 2001, Dated Oct. 25, 2005.
PCT Application Publication No. PCT/US97/04427 for Sloan-Kettering Institute for Cancer Research et al., Filed Mar. 20, 1997 for “Single Chain FV Constructs of Anti-ganglioside GD”, Published with International Search Report.
European Patent Office Supplementary Search Report for Sloan-Kettering Institute for the Cancer Research, Int'l No. PCT/US03/07004, Filed Mar. 4, 2003 Dated Oct. 25, 2005.
Cheung, N. K. V. et al., Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol., 16:3053-3060, 1998. (Exhibit 1).
Yu, A. et al. et al., Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol., 16:2169-2180, 1998. (Exhibit 2).
Jurcic, J. G. et al., Sequential targeted therapy for acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leuk., 9:244-248, 1995. (Exhibit 3).
Czuczman, M. S. et al., Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol., 17:268-276, 1999. (Exhibit 4).
Garin-Chesa, P. et al, Immunohistochemical analysis of neural cell adhesion molecules. Differential expressionin small round cell tumors of childhood and adolescence. Am. J. Pathol., 139:275-286, 1991. (Exhibit 5).
Ritter, G. et al, Ganglioside antigens expressed by human cancer cells. Semin. Cancer Biol., 2:401-409, 1991. (Exhibit 6).
Ylagan et al., CD44 expression in astrocytic tumors. Modern Pathology, 10:1239-1246, 1997. (Exhibit 7).
Kuan, C. T. et al., 125I-labeled anti-epidermal growth factor receptor vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin. Can. Res., 5:1539-1549, 1999. (Exhibit 8).
Richardson, R. B. et al., Radioimmunolocalization of human brain tumors. Biodistribution of radiolabelled monoclonal antibody UJ13A. Eur J Nucl Med, 12:313-320, 1986. (Exhibit 9).
Papanastassiou, V. et al., Treatment of recurrent and cystic malignant gliomas by a single intracavitary injection of 131I-monoclonal antibody: Feasibility, pharmacokinetics and dosimetry. Br. J. Cancer, 67:144-151, 1993. (Exhibit 10).
Celis, E. et al., Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91:2105-2109, 1994. (Exhibit 11).
Riva, P. et al., 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma- phase I and II study. Acta Oncol, 38:351-359, 1999. (Exhibit 12).
Heiner, J. et al., Localization of GD2 specific monoclonal antibody in human osteogenic sarcoma. Cancer Res., 47:5377-5381, 1987. (Exhibit 13).
Spendlove, I. et al., Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res., 59:2282-2286, 1999, (Exhibit 14).
Weidner, N. et al., Immunohistochemical profile of monoclonal antibody O13 that recognizes glycoprotein 930/32MIC2 and is useful in diagnosing ewing's sarcoma and peripheral neuroepithelioma. American Journal of Surgical Pathology 18:486-494, 1994. (Exhibit 15).
Hatzubai, A. et al., The use of a monoclonal anti-idiotype antibody to study the biology of human B-cell lymphoma. J. Immunol., 126:2397-2402, 1981. (Exhibit 16).
Cheung, N. K. et al., Monoclonal antibodies to a glyc

Affiliated with

Also associated with

Rating

Uses of monoclonal antibody 8H9 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of monoclonal antibody 8H9, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of monoclonal antibody 8H9 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4248806